Alpha Teknova (TKNO) Total Non-Current Liabilities (2020 - 2025)
Alpha Teknova's (TKNO) quarterly Total Non-Current Liabilities came in at $34.8 million in Q4 2025, down 4.28% year-on-year from $36.4 million in Q4 2024, and little changed on a QoQ basis from $35.0 million in Q3 2025.
Alpha Teknova (TKNO) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
Alpha Teknova (TKNO) has 6 years of Total Non-Current Liabilities data on file, last reported at $34.8 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 4.28% year-over-year to $34.8 million in Q4 2025; TTM through Dec 2025 was $34.8 million, a 4.28% decrease from a year earlier, with the FY2025 full-year figure at $34.8 million, down 4.28% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $34.8 million, roughly flat from $35.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for TKNO reached as high as $52.2 million in Q4 2022 and fell as low as $22.6 million in Q3 2021.
- Historically, Total Non-Current Liabilities has averaged $38.0 million across 5 years, with a median of $36.8 million in 2024.
- Across the five-year window, Total Non-Current Liabilities surged 126.81% in 2021 and decreased 26.32% in 2023, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $23.0 million in 2021, then surged by 126.55% to $52.2 million in 2022, then decreased by 26.32% to $38.4 million in 2023, then dropped by 5.42% to $36.4 million in 2024, then dropped by 4.28% to $34.8 million in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $34.8 million in Q4 2025, $35.0 million in Q3 2025, and $34.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Alpha Teknova | 278.75 Mn | 260.97 Mn | 3.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.81 Mn |
| Sep 30, 2025 | 34.98 Mn |
| Jun 30, 2025 | 34.43 Mn |
| Mar 31, 2025 | 35.39 Mn |
| Dec 31, 2024 | 36.37 Mn |
| Sep 30, 2024 | 36.80 Mn |
| Jun 30, 2024 | 36.37 Mn |
| Mar 31, 2024 | 37.36 Mn |
| Dec 31, 2023 | 38.45 Mn |
| Sep 30, 2023 | 38.61 Mn |
| Jun 30, 2023 | 46.19 Mn |
| Mar 31, 2023 | 48.77 Mn |
| Dec 31, 2022 | 52.19 Mn |
| Sep 30, 2022 | 48.06 Mn |
| Jun 30, 2022 | 48.50 Mn |
| Mar 31, 2022 | 45.28 Mn |
| Dec 31, 2021 | 23.04 Mn |
| Sep 30, 2021 | 22.64 Mn |
| Jun 30, 2021 | 23.22 Mn |
| Dec 31, 2020 | 10.16 Mn |